The infusion of capital, supported by heavyweights including T. Rowe Price Investment Management, Venrock Healthcare Capital Partners, and Wellington Management, is intended to sustain operations through 2029. This funding arrives as Alaunos pivots toward the development of treatments for pulmonary arterial hypertension and related cardiopulmonary conditions, the core focus of the newly acquired Velaris portfolio.

As part of the restructuring, Fairmount founding partner Peter Harwin will join the board. The governance transition is expected to continue until Fairmount designees hold four of the five available seats, effectively placing the company’s future direction under the control of its new lead investors. Despite the recent rally, the stock remains down approximately 9% for the year.